PL - Lipfendra - Antilipidemics-1 - PCSK-9.xlsx

XLSX spreadsheet 45 KB Posted

Attached to
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation number
HT9402-26-Q-9402
Issued by

About this file

This is a pricing template and specification document for pharmaceutical quotes under the Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement and Uniform Formulary Additional Discount Program for the November 2026 P&T Committee meeting. The document establishes quote requirements for Lipfendra (PCSK-9 antilipidemic agents) across ten newly approved drug scenarios, with quotes due August 27, 2026, for evaluation at the November 4-5, 2026 P&T Committee meeting. The Defense Health Agency will award BPA and ADP agreements based on clinical and cost effectiveness evaluations conducted per 10 U.S.C. 1074g and 32 CFR Section 199.21.

The pricing structure includes three submission pathways: (1) Blanket Purchase Agreement pricing for Military Treatment Facility and Mail Order channels offering Uniform Formulary After-Step and Non-Formulary After-Step scenarios with price-per-unit requirements; (2) Additional Discount Program (non-FAMP Discount) for TRICARE Retail with Tier 2 and Tier 3 after-step formulations requiring non-FAMP pricing, additional offered refund percentages, and current annual Federal Ceiling Price data; and (3) Additional Discount Program (WAC Discount) for TRICARE Retail using Wholesale Acquisition Cost pricing with discount percentages. All pricing must be uniform across package sizes within a given dispensing venue. Manufacturers must submit completed Quote Review Checklists and fully executed signature pages. Prior authorization requirements and step therapy protocols apply, with grandfathering provisions allowing patient exemption after 180 or 365 days of prior agent use. Agents without submitted or selected quotes may be designated non-step preferred status.

View the file

Other files

File Type Posted
PL - Trutakna - Nephrology Ag Misc - NA.xlsx XLSX spreadsheet
RFQ HT9402-26-Q-9402 NAD.pdf PDF
PL - Cavhanza - Leukemia N Lymphoma Ag - BCR-ABL TKIs.xlsx XLSX spreadsheet
PL - Awiqli - Insulin - Basal.xlsx XLSX spreadsheet
Formulary Placement of FDA NADs.pdf PDF
Price Appendix FAQ NAD.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 or 365 days (as determined by the P&T Committee) in order to be excluded from the prior authorization process.

Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#2DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1233ALPCG1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
233ALPCG1NFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (non-FAMP Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 or 365 days (as determined by the P&T Committee) in order to be excluded from the prior authorization process.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (WAC Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 or 365 days (as determined by the P&T Committee) in order to be excluded from the prior authorization process.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DoW Uniform Formulary Class:ANTILIPIDEMICS-1P&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:PCSK-9Quotes due:August 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1233ALPCG1T2AS1MTier 2
After Step1 or more
233ALPCG1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

File details come from the government source that posted it. Updated .